/
In vitro & in vivo diagnostic substances company · E9 · FY ends Dec · Revenue $9M · 66.70% margin
Margins and capital returns are both well above average: 66.70% operating margin, ROIC at 19.25%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 5.6%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$9M
▲ +5.6% YoY
Net Income (TTM)
$6M
▲ +169.9% YoY
Op. Margin
66.70%
▲ +42.3pp YoY
ROIC
19.25%
▲ +9.4pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$7M
▼ -423.9% YoY
Net Debt
-$12M
Net Cash Position
Cash & Equiv.
$12M
3Y CAGR: -28.4%
Continue Research